

# London – Stanmore Research Ethics Committee

Health Research Authority Skipton House 80 London Road London SE1 6LH

Telephone: 020 7972 2561

<u>Please note</u>: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

29 January 2020

Dr Alice Turner Consultant Chest Physician/Reader in Respiratory Medicine University of Birmingham Birmingham B15 2TT

Dear Dr Turner

Study title:	The use of a personalised early warning decision
	support system with novel saliva bio-profiling to predict
	and prevent acute exacerbations of Chronic Obstructive
	Pulmonary Disease - 'Predict & Prevent AECOPD'
REC reference:	19/LO/1939
Protocol number:	RG_19-050
IRAS project ID:	261576

Thank you for your letter responding to the Committee's request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

### **Confirmation of ethical opinion**

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.

### Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

<u>Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS</u> <u>management permission (in Scotland) should be sought from all NHS organisations involved in</u> <u>the study in accordance with NHS research governance arrangements.</u> Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

### Registration of Clinical Trials

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a publicly accessible database. For this purpose, 'clinical trials' are defined as the first four project categories in IRAS project filter question 2. <u>Registration is a legal requirement for clinical trials</u> <u>of investigational medicinal products (CTIMPs)</u>, except for phase I trials in healthy volunteers (these must still register as a condition of the REC favourable opinion).

Registration should take place as early as possible and within six weeks of recruiting the first research participant at the latest. Failure to register is a breach of these approval conditions, unless a deferral has been agreed by or on behalf of the Research Ethics Committee ( see here for more information on requesting a deferral: <u>https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/</u>

As set out in the UK Policy Framework, research sponsors are responsible for making information about research publicly available before it starts e.g. by registering the research project on a publicly accessible register. Further guidance on registration is available at: <a href="https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/">https://www.hra.nhs.uk/planning-and-improving-research/research-planning/transparency-responsibilities/</a>

You should notify the REC of the registration details. We will audit these as part of the annual progress reporting process.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

## After ethical review: Reporting requirements

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report

The latest guidance on these topics can be found at <u>https://www.hra.nhs.uk/approvals-amendments/managing-your-approval/</u>.

### Ethical review of research sites

#### NHS/HSC sites

The favourable opinion applies to all NHS/HSC sites listed in the application subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non-NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

## Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document	Version	Date
Covering letter on headed paper [Predict&Prevent REC Cover Letter]		23 October 2019
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only)		
GP/consultant information sheets or letters [Predict & amp; Prevent GP letter]	2.0	11 November 2019
IRAS Application Form [IRAS_Form_15112019]		15 November 2019
Letter from funder [Intent to fund by primary contracting signatory]		01 February 2019
Letter from sponsor [Confirmation of willingness to Sponsor]		08 March 2019
Other [PIS Healthcare Professionals]	2.0	17 January 2020
Other [Tracked changes Predict&Prevent Healthcare Professional Interview Study Participant Information Sheet and Consent Form]	2.0 Tracked changes	17 January 2020
Participant consent form [Predict & Prevent ICF v3.0]	3.0	13 January 2020

Participant information sheet (PIS) [Participant Information Sheet]	3.0	13 January 2020
Research protocol or project proposal [Predict & Prevent Protocol]	2.0 Tracked Changes	13 January 2020
Research protocol or project proposal [Predict & Prevent protocol]	3.0	13 January 2020
Summary CV for Chief Investigator (CI) [CICV]		02 October 2019
Summary, synopsis or diagram (flowchart) of protocol in non technical language [Flow Diagram]	1.0	26 September 2019
Validated questionnaire [Example booklet. Similar versions available at other time points]		

# Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

## User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: <u>http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/</u>

### **HRA Learning**

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities— see details at: <u>https://www.hra.nhs.uk/planning-and-improving-research/learning/</u>

## 19/LO/1939

Please quote this number on all correspondence

With the Committee's best wishes for the success of this project.

Yours sincerely

pp Mrs Sunder Chita Chair

Email:nrescommittee.london-stanmore@nhs.net

*Enclosures:* "After ethical review – guidance for researchers"

Copy to: Dr Birgit Whitman